Summary
For almost 20 years, anticonvulsant monotherapy has been regarded as the ideal method of management of epilepsy. This line of thought, while true, has mutated into a general view of polypharmacy with anticonvulsants as a sign of therapeutic failure. However, even when the ‘right’ drug is given at the ‘right’ dose, studies have shown that in around 30% of patients, epilepsy will not fully respond to anticonvulsant monotherapy. For these patients, polypharmacy with anticonvulsants is an inevitability.
There are good reasons why the established anticonvulsants should not be particularly well tolerated in combination. However, anticonvulsant polypharmacy has become so ‘undesirable’ that there has been a failure to search for firm treatment strategies for refractory epilepsy. Nevertheless, there are strong arguments to suggest that the newer anticonvulsants will prove to be better tolerated in combination than their established counterparts, particularly in view of their paucity of drug interactions, more predictable pharmacokinetics and narrower spectrum of action.
This review calls for the development of a rational plan for the treatment of refractory epilepsy. Proper double-blind trials should be carried out to compare the efficacy and tolerability of anticonvulsant drug combinations. This is a huge task that could be rationalised by concentrating on combinations that have been reported to have particular benefit, or those with neurochemical properties that suggest an additive or even synergistic effect.
Similar content being viewed by others
References
Goodridge DMG, Shorvon SD. Epileptic seizures in a population of 6000. 1: Demography, diagnosis and classification. BMJ 1983; 287: 641–4
Goodridge DMG, Shorvon SD. Epileptic seizures in a population of 6000. 2: Treatment and prognosis. BMJ 1983; 287: 645–7
Shorvon SD. Epidemiology, classification, natural history, and genetics of epilepsy. Lancet 1990; 336: 93–6
Brodie MJ, Dichter M. Anticonvulsant drugs. N Engl J Med 1996; 334: 168–75
Leach JP, Brodie MJ. New antiepileptic drugs: an explosion of activity. Seizure 1995; 4: 5–17
Reynolds EH. Changing view of the prognosis of epilepsy. BMJ 1990; 301: 1112–4
Dichter MA, Brodie MJ. The new antiepileptic drugs. N Engl J Med 1996; 334: 1583–90
Mattson RH, Cramer JA, Collins JF, et al. Comparison of phenobarbital, phenytoin and primidone in partial and secondary generalised tonic-clonic. N Engl J M 1985; 313: 145–51
Mattson RH. Effects of established and new antiepileptic drugs. Epilepsia 1995; 36 Suppl. 2: 13–26
Walker MC, Sander JWAS. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996; 46: 912–4
Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476–9
Mawer GE, Pleuvry BJ. Interactions involving new antiepileptic drugs. Pharmacol Ther 1995; 68: 209–31
Brodie MJ. Drug interactions and epilepsy. Epilepsia 1992; 33: 13–22
Koller WC, Silver DE, Lieberman A. An algorithm for the management of PD. Neurology 1994; 44 Suppl. 10: 1–51
Shorvon SD, Reynolds EH. Unnecessary polypharmacy for epilepsy. BMJ 1977; 1: 1635–7
Shorvon SD, Reynolds EH. Reduction of polypharmacy for epilepsy. BMJ 1979; 2: 1023–5
Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy. Epilepsia 1981; 22: 1–10
Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy. CNS Drugs 1995; 3: 194–208
Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995; 37: 97–108
Kalviainen R, Aikia M, Saukkonen AM, et al. Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized, controlled study. Arch Neurol 1995; 52: 989–96
Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982; 23: 693–720
Chadwick DW. Diagnosis of epilepsy. Lancet 1990; 336: 291–5
Loiseau P. Benign focal epilepsies of childhood. In: Wyllie E, editor. The treatment of epilepsy: principles and practice. Philadelphia: Lea and Febiger, 1993: 584–94
Dulac O, Nguyen T. The Lennox Gastaut syndrome. Epilepsia 1993; 34 Suppl. 7: 7–17
Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology 1984; 34: 1252–5
Schmidt D. Single drug therapy for intractable epilepsy. J Neurology 1983; 229: 221–6
McKee PJW, Blacklaw J, Butler E, et al. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. Br J Clin Pharmacol 1991; 32: 99–104
Persson LI, BenMenachem E, Bengtsson E, et al. Differences in side effects between a conventional carbamazepine preparation and a slow release preparation of carbamazepine. Epilepsy Res 1990; 6: 137–40
Imaizumi T, Izumi T, Fukuyama Y. A comparative clinical and pharmacokinetic study of a new slow release versus conventional forms of valproic acid in children with epilepsy. Brain Dev 1992; 14: 304–8
Hakkareinen H. Carbamazepine versus phenytoin vs their combination in refractory epilepsy [abstract]. Neurology 1980; 30: 354
Dean JC, Penry JK. Carbamazepine/valproate therapy in 100 patients with partial seizures failing carbamazepine monotherapy: long term follow up [abstract]. Epilepsia 1988; 29: 687
Nakane Y, Okuma T, Takashi R, et al. Multi-institutional study of the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980; 21: 663–80
Beghi E, Di Mascio R, Tognoni G. Drug treatment of epilepsy: outlines, criticism and perspectives. Drugs 1986; 31: 249–65
Lammers MW, Hekster YA, Keyser A, et al. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia 1995; 36: 440–6
Pritchard JW, Ransom BR. Phenobarbital — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 359–70
Delorenzo RJ. Phenytoin — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 271–2
Meldrum BS. Update on mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 Suppl. 6: 4–11
MacDonald RL. Carbamazepine — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 491–8
Fanello RG, Varasi M, Smith MC. Sodium valproate — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 581–8
MacDonald RL. Benzodiazepines — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 695–703
Jung MJ, Palfreyman MG. Vigabatrin — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 903–13
Leach MJ, Lees G, Riddali DR. Lamotrigine — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 861–9
Taylor CP. Gabapentin — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 829–41
Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35: 450–60
Wilder BJ. The treatment of epilepsy: an overview of clinical practices. Neurology 1995: 45 Suppl. 2: 7–11
Rogawski M, Porter R. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990; 42: 223–86
Dam M, Ostergaard LH. Potential antiepileptic drugs — oxcarbazepine. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 987–96
Nielsen EB, Suzdak PD, Andersen KE, et al. Characterisation of tiagabine, a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991; 196: 257–66
Ostergaard LH, Gram L, Dam M. Potential antiepileptic drugs — tiagabine. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 1057–62
Taylor CP. Mechanism of action of new antiepileptic drugs. In: Chadwick D, editor. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services, 1993: 13–40
MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995; Suppl. 2: 2–12
Chez MG, Bourgeois BF, Pippenger GE, et al. Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice. Clin Neuropharmacol 1994; 17: 32–7
Bourgeois BF. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin Neuropharmacol 1988; 11: 348–59
Bourgeois BF. Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J Pharmacol Exp Ther 1988; 247: 1128–32
Bourgeois BF. Antiepileptic drug combinations and experimental background: the case of phenobarbital and phenytoin. Naunyn Schmiebergs Arch Pharmacol 1986; 333: 406–11
Bourgeois BF, Wad N. Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity. Epilepsia 1988; 29: 482–7
Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 1995; 36 Suppl. 5: 1–7
Leach JP, Sills GJ, Majid A, et al. Effects of tiagabine and vigabatrin on GABA uptake into primary cultures of rat cortical astrocytes. Seizure 1996; 5: 229–34
Cereghino JJ, Penry JK. Introduction. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 1–11
Meunier H, Carraz G, Meunier Y, et al. Properietes pharmacodynamiques de lacide n-dipropylacetique. Therapie 1963; 18: 435–8
Stewart J, Hughes E, Kirker S, et al. Combined vigabatrin and lamotrigine for very refractory epilepsy. Seizure 1992; 1 Suppl. A: 13–39
Brodie MJ, Yuen AWC and the 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res 1997; 26: 423–6
Richens A. Rational polypharmacy. Seizure 1995; 4: 211–4
Panayiotopoulos CP, Ferrie CD, Knott C, et al. Interaction of lamotrigine and sodium valproate [letter]. Lancet 1993; 341: 445
Klitgaard H, Knudsen ML, Jackson HC. Synergism between drugs with different mechanisms of action against audiogenic seizures in DBA/2 mice [abstract]. Epilepsia 1993; 34 Suppl. 6: 93
Leach JP, Sills GJ, Thompson G, et al. The neurochemical effects of tiagabine and vigabatrin alone and in combination in mouse cortex. Gen Pharmacol 1997; 28: 715–9
Leach JP, Sills GJ, Butler E, et al. Neurochemical actions of gabapentin in mouse brain. Epilepsy Res 1997; 27: 175–80
Petroff OAC, Rothman DL, Behar KL, et al. The effect of gabapentin on brain GABA in patients with epilepsy. Ann Neurol 1996; 39: 95–9
Sills GJ, Leach JP, Butler E, et al. Neurochemical studies with topiramate in mouse brain [abstract]. Epilepsia 1997; Suppl. 3: 177
Sills GJ, Leach JP, Fraser CM, et al. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol 1997; 325: 35–40
Leach JP, Sills GJ, Butler E, et al. Neurochemical actions of the desglycinyl metabolite of remacemide hydrochloride (ARL 12495 AA) in mouse brain. Br J Pharmacol 1997; 121: 923–6
McKee PJW, Blacklaw J, Friel E, et al. Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients? Epilepsia 1993; 34: 937–43
Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889–926
Swinyard EA, Woodhead JH, Wolf HH. Use of isobolograms in predicting drug interactions. In: Pitlick WH, editor. Antiepileptic drug interactions. New York: Publ Demos, 1989: 261–75
Mattson RH. Antiepileptic drug monitoring: a reappraisal. Epilepsia 1995; 36 Suppl. 2: 22–9
Ferrendelli JA. Rational polypharmacy. Epilepsia 1995; 36 Suppl. 2: 115–8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leach, J.P. Polypharmacy with Anticonvulsants. CNS Drugs 8, 366–375 (1997). https://doi.org/10.2165/00023210-199708050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199708050-00003